Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Ian M Bell

C Blair Zartman

Craig A Stump

Steven N Gallicchio

Harold G Selnick

Cory R Theberge

Mark E Fraley

Donnette D Staas

Brendan M Crowley

Helen J Mitchell

Anthony T Ginnetti

Michael R Wood

Daniel Vincent Paone

Cheng Wang

Andrew John Harvey

Theresa M Williams

Brian T Campbell

Kenneth J Leavitt

Deodial Guy Guiadeen

Christopher S Burgey

Thomas J Greshock

Wayne J Thompson

Vanessa L Rada

Xufang Zhang

Joseph P Vacca

Tesfaye Biftu

Neville J Anthony

Roger M Freidinger

Christopher J Dinsmore

Ashok Arasappan

Peter D Williams

Shawn J Stachel

James J Perkins

Jian Liu

Douglas C Beshore

Jason M Cox

Mark E Layton

Hong Liu

Cheng Zhu

Harry R Chobanian

Christopher James Bungard

William D Shipe

Anilkumar G Nair

Richard W Ransom

Xu-Fang Zhang

Belinda C Huff

Michael F Sugrue

Heather E Stevenson

Zhe Wu

Pierre J Mallorga

John M Sanders

Samuel L Graham

John S Wai

Robert P Gomez

Michael J Breslin

Dharam Paul

Joseph Leslie Duffy

Peter M Munson

James P Guare

Anthony M Smith

Christophe Morice

Debra S Perlow

Kristen L G Jones

Michelle A Sparks

Christophe Joseph

Linda M Suen-Lai

Howard G Selnick

Linda M Suen

John Howard Hutchinson

William C Lumma, Jr

Valentino J Stella

Gerald E Stokker

S Jane deSolms

Thomas Joseph Tucker

Steven D Young

Anthony W Shaw

Peter J Manley

Bruno Giethlen

Joel R Huff

Anthony J Roecker

Mark W Embrey

Terrence M Ciccarone

Michael J Kelly, Iii

Thorsten E Fisher

Thomas G Steele

Rajinder Singh

Lekhanh O Tran

Melody McWherter

Justin Ripper

June J Kim

Jean-Marie Contreras

Kenneth J Stauffer

Laurent Schaeffer

Jennie B Nerenberg

Thomas Avery

S Jane De Solms

Daria Jean Hazuda

Jeffrey W Schubert

James I Fells

Fabrice Garrido

The present disclosure relates to compounds of formula I that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation

Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors

2-oxoimidazolidine-4-carboxamides as NA1.8 inhibitors

The present disclosure relates to compounds of formula I that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation

Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Na1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders. 

2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors

The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I). 

Heteroaryl allosteric modulators of nicotinic acetylcholine receptors

The present disclosure relates to compounds of formula (I) that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation. 

Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors

The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Piperidinone carboxamide azaindane CGRP receptor antagonists

Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein 'R', 'R', &#x201c;R&#x201d;, &#x201c;R&#x201d;, &#x201c;R&#x201d;, are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (&#x3b1;7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof

The present disclosure relates to compounds of formula I that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation 

Allosteric modulators of nicotinic acetylcholine receptors

Growing community of inventors

Harleysville, PA, United States of America

Ian M Bell